Prostate cancer progression:: Sodium salicylate, the active metabolite of aspirin inhibits nuclear factor-kappa B (NFkB) pathway

Olaniyi Ogundiya; Helen Whiteland; U. K. Shah; O. Bodger; H. Haboubi; H. Kynaston; S. Doak

doi:10.1016/j.ijsu.2018.05.038

Crynodeb

Aim: Evidence from several studies suggests that nuclear factor-kappa B (NFκB) pathway is associated with cancer progression. Therefore, the inhibition of the NFκB pathway provides the focus for cancer management. Sodium salicylate, the active metabolite of aspirin has been shown to inhibit NFκB activation in prostate cell lines. In this study, we examine the role of NFκB pathway in PNT2 (normal prostate), DU145 (prostatic brain metastasis), PC3 (prostatic bone metastasis).

Method: We exposed both normal prostate (PNT2) cells and prostate cancer (DU145, PC3) cell lines to sodium salicylate. NFκB activation in prostate cells was examined by ELISA (enzyme-linked immunosorbent assay) alongside controls. IKK an inhibitor of NFκB activation and tumour necrosis factor (TNF) a potent activator of NFκB were utilised as controls.

Result: Our results suggest that sodium salicylate inhibits NFκB activation in prostate cancer cell lines. PC3 (the most aggressive cell line) showed a decreased level of NFκB activation after treatment with sodium salicylate. However, PNT2 and DU145 showed very little change in NFκB activation over the dose ranges applied.

Conclusion: Our study provides further evidence that NFκB pathway is associated with prostate cancer progression as we observed NFκB activation and inhibition by sodium salicylate in all three prostatic cell lines.

Iaith wreiddiol	Saesneg
Tudalennau	S13-S14
Nifer y tudalennau	2
Dynodwyr Gwrthrych Digidol (DOIs)	https://doi.org/10.1016/j.ijsu.2018.05.038
Statws	E-gyhoeddi cyn argraffu - 02 Awst 2018
Digwyddiad	Association of Surgeons In Training International Surgical Conference 2018 - Edinburgh International conference Centre, Edinburgh, Teyrnas Unedig Prydain Fawr a Gogledd Iwerddon Hyd: 06 Ebr 2018 → 08 Ebr 2018

Cynhadledd

Cynhadledd	Association of Surgeons In Training International Surgical Conference 2018
Teitl cryno	ASiT
Gwlad/Tiriogaeth	Teyrnas Unedig Prydain Fawr a Gogledd Iwerddon
Dinas	Edinburgh
Cyfnod	06 Ebr 2018 → 08 Ebr 2018

NDC y CU

Mae’r allbwn hwn yn cyfrannu at y Nod(au) Datblygu Cynaliadwy canlynol

Mynediad at Ddogfen

10.1016/j.ijsu.2018.05.038

Cysylltiad parhaol

Dolen barhaus

Dyfynnu hyn

Ogundiya, O., Whiteland, H., Shah, U. K., Bodger, O., Haboubi, H., Kynaston, H., & Doak, S. (2018). Prostate cancer progression: Sodium salicylate, the active metabolite of aspirin inhibits nuclear factor-kappa B (NFkB) pathway. S13-S14. Ffurflen grynodeb Association of Surgeons In Training International Surgical Conference 2018, Edinburgh, Teyrnas Unedig Prydain Fawr a Gogledd Iwerddon. https://doi.org/10.1016/j.ijsu.2018.05.038

@conference{8cd815cb46a0416b9ad6312295247b61,

title = "Prostate cancer progression:: Sodium salicylate, the active metabolite of aspirin inhibits nuclear factor-kappa B (NFkB) pathway",

abstract = "Aim: Evidence from several studies suggests that nuclear factor-kappa B (NFκB) pathway is associated with cancer progression. Therefore, the inhibition of the NFκB pathway provides the focus for cancer management. Sodium salicylate, the active metabolite of aspirin has been shown to inhibit NFκB activation in prostate cell lines. In this study, we examine the role of NFκB pathway in PNT2 (normal prostate), DU145 (prostatic brain metastasis), PC3 (prostatic bone metastasis).Method: We exposed both normal prostate (PNT2) cells and prostate cancer (DU145, PC3) cell lines to sodium salicylate. NFκB activation in prostate cells was examined by ELISA (enzyme-linked immunosorbent assay) alongside controls. IKK an inhibitor of NFκB activation and tumour necrosis factor (TNF) a potent activator of NFκB were utilised as controls.Result: Our results suggest that sodium salicylate inhibits NFκB activation in prostate cancer cell lines. PC3 (the most aggressive cell line) showed a decreased level of NFκB activation after treatment with sodium salicylate. However, PNT2 and DU145 showed very little change in NFκB activation over the dose ranges applied.Conclusion: Our study provides further evidence that NFκB pathway is associated with prostate cancer progression as we observed NFκB activation and inhibition by sodium salicylate in all three prostatic cell lines.",

author = "Olaniyi Ogundiya and Helen Whiteland and Shah, {U. K.} and O. Bodger and H. Haboubi and H. Kynaston and S. Doak",

year = "2018",

month = aug,

day = "2",

doi = "10.1016/j.ijsu.2018.05.038",

language = "English",

pages = "S13--S14",

note = "Association of Surgeons In Training International Surgical Conference 2018, ASiT ; Conference date: 06-04-2018 Through 08-04-2018",

}

Ogundiya, O, Whiteland, H, Shah, UK, Bodger, O, Haboubi, H, Kynaston, H & Doak, S 2018, 'Prostate cancer progression: Sodium salicylate, the active metabolite of aspirin inhibits nuclear factor-kappa B (NFkB) pathway', Association of Surgeons In Training International Surgical Conference 2018, Edinburgh, Teyrnas Unedig Prydain Fawr a Gogledd Iwerddon, 06 Ebr 2018 - 08 Ebr 2018 tt. S13-S14. https://doi.org/10.1016/j.ijsu.2018.05.038

Prostate cancer progression: Sodium salicylate, the active metabolite of aspirin inhibits nuclear factor-kappa B (NFkB) pathway. / Ogundiya, Olaniyi; Whiteland, Helen; Shah, U. K. et al.
2018. S13-S14 Ffurflen grynodeb Association of Surgeons In Training International Surgical Conference 2018, Edinburgh, Teyrnas Unedig Prydain Fawr a Gogledd Iwerddon.

Allbwn ymchwil: Cyfraniad at gynhadledd › Crynodeb › adolygiad gan gymheiriaid

TY - CONF

T1 - Prostate cancer progression:

T2 - Association of Surgeons In Training International Surgical Conference 2018

AU - Ogundiya, Olaniyi

AU - Whiteland, Helen

AU - Shah, U. K.

AU - Bodger, O.

AU - Haboubi, H.

AU - Kynaston, H.

AU - Doak, S.

PY - 2018/8/2

Y1 - 2018/8/2

N2 - Aim: Evidence from several studies suggests that nuclear factor-kappa B (NFκB) pathway is associated with cancer progression. Therefore, the inhibition of the NFκB pathway provides the focus for cancer management. Sodium salicylate, the active metabolite of aspirin has been shown to inhibit NFκB activation in prostate cell lines. In this study, we examine the role of NFκB pathway in PNT2 (normal prostate), DU145 (prostatic brain metastasis), PC3 (prostatic bone metastasis).Method: We exposed both normal prostate (PNT2) cells and prostate cancer (DU145, PC3) cell lines to sodium salicylate. NFκB activation in prostate cells was examined by ELISA (enzyme-linked immunosorbent assay) alongside controls. IKK an inhibitor of NFκB activation and tumour necrosis factor (TNF) a potent activator of NFκB were utilised as controls.Result: Our results suggest that sodium salicylate inhibits NFκB activation in prostate cancer cell lines. PC3 (the most aggressive cell line) showed a decreased level of NFκB activation after treatment with sodium salicylate. However, PNT2 and DU145 showed very little change in NFκB activation over the dose ranges applied.Conclusion: Our study provides further evidence that NFκB pathway is associated with prostate cancer progression as we observed NFκB activation and inhibition by sodium salicylate in all three prostatic cell lines.

AB - Aim: Evidence from several studies suggests that nuclear factor-kappa B (NFκB) pathway is associated with cancer progression. Therefore, the inhibition of the NFκB pathway provides the focus for cancer management. Sodium salicylate, the active metabolite of aspirin has been shown to inhibit NFκB activation in prostate cell lines. In this study, we examine the role of NFκB pathway in PNT2 (normal prostate), DU145 (prostatic brain metastasis), PC3 (prostatic bone metastasis).Method: We exposed both normal prostate (PNT2) cells and prostate cancer (DU145, PC3) cell lines to sodium salicylate. NFκB activation in prostate cells was examined by ELISA (enzyme-linked immunosorbent assay) alongside controls. IKK an inhibitor of NFκB activation and tumour necrosis factor (TNF) a potent activator of NFκB were utilised as controls.Result: Our results suggest that sodium salicylate inhibits NFκB activation in prostate cancer cell lines. PC3 (the most aggressive cell line) showed a decreased level of NFκB activation after treatment with sodium salicylate. However, PNT2 and DU145 showed very little change in NFκB activation over the dose ranges applied.Conclusion: Our study provides further evidence that NFκB pathway is associated with prostate cancer progression as we observed NFκB activation and inhibition by sodium salicylate in all three prostatic cell lines.

U2 - 10.1016/j.ijsu.2018.05.038

DO - 10.1016/j.ijsu.2018.05.038

M3 - Abstract

SP - S13-S14

Y2 - 6 April 2018 through 8 April 2018

ER -

Ogundiya O, Whiteland H, Shah UK, Bodger O, Haboubi H, Kynaston H et al.. Prostate cancer progression: Sodium salicylate, the active metabolite of aspirin inhibits nuclear factor-kappa B (NFkB) pathway. 2018. Ffurflen grynodeb Association of Surgeons In Training International Surgical Conference 2018, Edinburgh, Teyrnas Unedig Prydain Fawr a Gogledd Iwerddon. Epub 2018 Awst 2. doi: 10.1016/j.ijsu.2018.05.038

Prostate cancer progression: Sodium salicylate, the active metabolite of aspirin inhibits nuclear factor-kappa B (NFkB) pathway